ArticleSignal transduction and targeted therapy2025
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs.
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Metabolism, autophagy, and cell death: The triangular axis in tumor survival and therapeutic resistance.Redox biology · 2026Review
- Secreted luciferases as a minimally invasive 3R-compliant tool for accurate monitoring of tumor burden.Nature protocols · 2026Review
- The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.Cancers · 2026Review
- SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.International journal of molecular sciences · 2026Article
- Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop.Cell death & disease · 2026Article
- mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HRCell death & disease · 2026Article
- Comparison of ABQ-48 Multimodal Cytotoxicity Mechanism Against Lung, Colorectal, and Breast Cancer Cells.Current issues in molecular biology · 2026Article
- Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets.Communications chemistry · 2026Article
- CDCA7 promotes chemoresistance of drug-tolerant persister cells in breast cancer by upregulating the expression of autophagy-related protein genes.Frontiers in immunology · 2026Article
- Targeting PIP5K ameliorates hepatic cancer by inhibiting PI3K/AKT and the autophagy mechanism and enhancing ROS-mediated apoptosis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Niklas GremkeInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany. Gremken@staff.uni-marburg.de.ORCID 0000-0002-9015-3646
Isabelle BesongInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Alina StrohInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Luise von WichertInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Marie WittInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Sabrina ElmshäuserInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Michael WanzelInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Martin F FrommInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
R Verena TaudteCore Facility for Metabolomics, Philipps University, Marburg, Germany.
Sabine SchmatlochElisabeth Hospital Kassel, Kassel, Germany.
Thomas KarnUCT Frankfurt-Marburg, Department of Gynecology and Obstetrics, Goethe University, Frankfurt, Germany.ORCID 0000-0002-3264-6573
Mattea ReinischBreast Unit, University Hospital Mannheim, Mannheim, Germany.ORCID 0000-0002-1381-8595
Nader HirmasGerman Breast Group (GBG), Neu-Isenburg, Germany.
Sibylle LoiblGerman Breast Group (GBG), Neu-Isenburg, Germany.
Thomas WündischUCT Frankfurt-Marburg, Comprehensive Cancer Center Marburg, University Hospital Gießen and Marburg Campus Marburg, Philipps-University, Marburg, Germany.
Anne-Sophie LitmeyerInstitute of Pathology, University Hospital Gießen and Marburg Campus Marburg, Philipps-University, Marburg, Germany.
Paul JankInstitute of Pathology, University Hospital Gießen and Marburg Campus Marburg, Philipps-University, Marburg, Germany.ORCID 0000-0001-7076-0476
Carsten DenkertInstitute of Pathology, University Hospital Gießen and Marburg Campus Marburg, Philipps-University, Marburg, Germany.
Sebastian GriewingDepartment of Gynecology, Gynecological Endocrinology and Oncology, University Hospital Gießen and Marburg Campus Marburg, Philipps-University, Marburg, Germany.
Uwe WagnerDepartment of Gynecology, Gynecological Endocrinology and Oncology, University Hospital Gießen and Marburg Campus Marburg, Philipps-University, Marburg, Germany.
Thorsten StieweInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.ORCID 0000-0003-0134-7826
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) GRK 2573/2 - 2024Deutsche Forschungsgemeinschaft (German Research Foundation) INST 90/1048-1 FUGGVon-Behring-Röntgen-Stiftung (Von Behring-Röntgen-Foundation) 70_0027
Abstract
Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR
Indexed as
Breast NeoplasmsClass I Phosphatidylinositol 3-KinasesDrug Resistance, NeoplasmMechanistic Target of Rapamycin Complex 1Phosphoinositide-3 Kinase InhibitorsAnimalsAutophagyCell Line, TumorFemaleHumansMiceSignal TransductionThiazolesXenograft Model Antitumor AssaysAlpelisibClass I Phosphatidylinositol 3-KinasesMechanistic Target of Rapamycin Complex 1Phosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanThiazoles
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.